Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance
2010; Wiley; Volume: 85; Issue: 5 Linguagem: Inglês
10.1002/ajh.21692
ISSN1096-8652
AutoresMario Ojeda‐Uribe, Claudine Caron, Nathalie Itzhar-Baïkian, Agathe Debliquis,
Tópico(s)Myeloproliferative Neoplasms: Diagnosis and Treatment
ResumoAmerican Journal of HematologyVolume 85, Issue 5 p. 396-396 CorrespondenceFree Access Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance† Mario Ojeda-Uribe, Mario Ojeda-Uribe [email protected] Service d'Hématologie Clinique, Hôpital E Muller, Mulhouse, FranceSearch for more papers by this authorClaudine Caron, Claudine Caron Pôle d'Hématologie-Transfusion, Centre de Référence sur la Maladie de Willebrand, Centre Hospitalier, Universitaire de Lille, Lille, FranceSearch for more papers by this authorNathalie Itzhar-Baikian, Nathalie Itzhar-Baikian Service d' Hematologie Biologique, Centre de Référence sur la Maladie de Willebrand, Assistance Publique-Hopitaux de Paris, Hôpital Antoine Béclère, Clamart, FranceSearch for more papers by this authorAgathe Debliquis, Agathe Debliquis Pôle de Biologie, Laboratoire d'Hématologie, Hôpital E Muller, Mulhouse, FranceSearch for more papers by this author Mario Ojeda-Uribe, Mario Ojeda-Uribe [email protected] Service d'Hématologie Clinique, Hôpital E Muller, Mulhouse, FranceSearch for more papers by this authorClaudine Caron, Claudine Caron Pôle d'Hématologie-Transfusion, Centre de Référence sur la Maladie de Willebrand, Centre Hospitalier, Universitaire de Lille, Lille, FranceSearch for more papers by this authorNathalie Itzhar-Baikian, Nathalie Itzhar-Baikian Service d' Hematologie Biologique, Centre de Référence sur la Maladie de Willebrand, Assistance Publique-Hopitaux de Paris, Hôpital Antoine Béclère, Clamart, FranceSearch for more papers by this authorAgathe Debliquis, Agathe Debliquis Pôle de Biologie, Laboratoire d'Hématologie, Hôpital E Muller, Mulhouse, FranceSearch for more papers by this author First published: 21 April 2010 https://doi.org/10.1002/ajh.21692Citations: 5 † Conflict of interest: Nothing to report. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Mohri H. Acquired von Willebrand syndrome: Features and management. Am J Hematol 2006; 81: 616– 623. 2 Kumar S,Pruthi RK,Nichols W. Acquired von Willebrand Disease. Mayo Clin Proc 2002; 77: 181– 187. 3 Kyle RA,Themeau TM,Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362– 1369. 4 Grimaldi D,Bartolucci P,Gouault-Hellmann M, et al. Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome. Thromb Haemost 2008; 99: 782– 783. 5 Mazoyer E,Fain O,Dhote R,Laurian Y. Is rituximab effective in acquired von Willebrand syndrome?. Br J Haematol 2009; 144: 967– 968. 6 Siaka C,Rugeri L,Caron C,Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand Syndrome. Haemophilia 2003; 9: 303– 308. Citing Literature Volume85, Issue5May 2010Pages 396-396 ReferencesRelatedInformation
Referência(s)